Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Assistance Publique - Hôpitaux de Paris
We proposed a randomized controlled trial between 3,4-diaminopyridine and placebo .
The main objective : improvement of fatigue by diminution of EMIF-SEP score between the arm treatment and placebo arm. The hypothesis tested is that the 3,4-DAP is efficacy in the fatigue of multiple sclerosis.
Age
18–60
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age \>= 18 years and = \<60 years
Patients with multiple sclerosis clinically defined and with MIFS-SEP score \> 44, without deficit sleep and without depression.
Patients without treatment by 3,4-DAP since 3 months
EDSS score \< 6
You may not be if
ASAT/ALAT \> 2 x ULN
MADRS \>= 20
Abnormality cardiac rhythm
Pregnancy
Asthma
Evolutive affection
Renal failure
Clareo Health | Efficacy of 3,4-DAP in Fatigue Associated With Multiple Sclerosis
